

PharmaMar commences clinical trial in US with new antitumour product, PM060184

- *PM060184 is a new marine-derived compound which has shown strong antitumour activity in preclinical models and a favourable safety profile in animal toxicology studies.*
- *In addition to the US, Phase I trials will be performed in hospitals in Spain and France.*

Madrid, 7 February 2011: PharmaMar SA (Grupo Zeltia, ZEL.MC) has announced the commencement of a Phase I clinical trial with PM060184 for patients with solid tumours. PM060184 is a marine-derived synthetically-produced compound which has shown strong *in vitro* and *in vivo* antitumour activity and a favourable safety profile in preclinical toxicology studies. PM060184 is PharmaMar's sixth compound under clinical development.

The trials will be performed in hospitals in the US, and also in France and Spain. The primary endpoints of this Phase I trial are to identify the dose limiting toxicity (DLT), the maximum tolerated dose (MTD) and the recommended dose (RD) of PM060184.

Additionally, the drug's pharmacokinetic profile will be defined and a preliminary evaluation of its antitumour activity in patients will be performed.

About PharmaMar

PharmaMar is Grupo Zeltia's biotechnology subsidiary; it is a world leader in discovering, developing and selling marine-based drugs to treat cancer. Yondelis® is Spain's first antitumour drug. Yondelis® is currently approved for STS in 33 countries outside the EEA, and in 10 of those countries for platinum-sensitive ROC as well (including Brazil and Canada). Yondelis® is approved for STS and platinum-sensitive ROC in all 30 countries of the EEA; in Switzerland it is approved for STS. Phase II clinical trials with Yondelis® are also under way on prostate, breast, lung and paediatric cancers. PharmaMar has five other compounds in clinical development: Aplidin®, Irvalec®, Zalypsis®, PM01183 and PM060184. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D programme.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer

care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genómica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

Important note

PharmaMar, which is headquartered in Madrid (Spain), is a subsidiary of Grupo Zeltia (Spanish stock exchange: ZEL), which has been listed on the Spanish Stock Exchange since 1963 and on Spain's Electronic Market since 1998. This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

For more information +34 91 444 4500

This note is also available on the PharmaMar web site: www.pharmamar.com and at Zeltia's web site: www.zeltia.com